Immunotherapy Approaches for Urothelial Bladder Cancer: Expert Guidance Through Challenging Cases Exploring the Fundamental Changes in Patient Care

Review these downloadable slides to gain expert perspective for optimal use of immune checkpoint inhibitors for patients with advanced bladder cancer. Faculty members Andrea Apolo MD Jean Hoffman-Censits MD Matthew I. Milowsky MD and Elizabeth R. Plimack MD MS explain the current clinical rational and use of these immunotherapy options. Click here to use our online tool to see how to select optimal therapy for your patients.

Share

Program Content

Activities

Clinical Rationale for Immunotherapy in Bladder Cancer
Mechanism of Action and Clinical Rationale for Immunotherapy in Bladder Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 12, 2018

Expires: February 11, 2019

Neoadjuvant and Adjuvant Immunotherapy in Bladder Cancer
Potential for Neoadjuvant and Adjuvant Immunotherapy Approaches in Bladder Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 13, 2018

Expires: February 12, 2019

First-line Immunotherapy for Advanced Bladder Cancer
First-line Immunotherapy for Advanced Bladder Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

Currently Approved Immunotherapy After Progression
Currently Approved Immunotherapy After Progression
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

Integrating Immune Checkpoint Inhibitors Into the Clinic
Integrating Immune Checkpoint Inhibitors Into the Clinic for Patients with Advanced Bladder Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

Supporters

Supported by educational grants from

Astellas Text

Merck Oncology

Seagen

Partners

BCAN

ProCE Banner